Development of a Gadolinium-Boron-Conjugated Albumin for MRI-Guided Neutron Capture Therapy.
MRI
albumin
boron neutron capture therapy
closo-dodecaborate
gadolinium contrast agents
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
04 Dec 2023
04 Dec 2023
Historique:
medline:
5
12
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
ppublish
Résumé
Noninvasive monitoring of boron agent biodistribution is required in advance of neutron capture therapy. In this study, we developed a gadolinium-boron-conjugated albumin (Gd-MID-BSA) for MRI-guided neutron capture therapy. Gd-MID-BSA was prepared by labeling bovine serum albumin with a maleimide-functionalized gadolinium complex and a maleimide-functionalized
Identifiants
pubmed: 37909734
doi: 10.1021/acs.molpharmaceut.3c00726
doi:
Substances chimiques
Boron
N9E3X5056Q
Gadolinium
AU0V1LM3JT
Maleimides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM